TrialCancer chemotherapy and pharmacology2022

Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.

Huybrecht T'jollyn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.